Print

U.S. Panel Backs Dendreon Corporation (DNDN)'s Provenge for Medicare  
11/18/2010 6:45:51 AM

WASHINGTON (Reuters) - A U.S. advisory panel backed Dendreon Corp's Provenge prostate cancer therapy on Wednesday, telling the Medicare insurance program for the elderly that available data showed it could help patients.
//-->